Plain-English translation of NCT07129993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called datopotamab deruxtecan () combined with chemotherapy for people with advanced bladder cancer that has continued to grow despite previous treatment with other drugs. Researchers want to see if this new medication, when paired with standard chemotherapy drugs like or , can help people live longer and control their cancer better than the current standard treatment ( chemotherapy). The study will first test the medication at two different doses to find the safest and most effective dose, then move to a larger phase to confirm whether it really works.
Many people with advanced bladder cancer do not respond well to current treatments, or their cancer returns after treatment. This medication is designed to target cancer cells in a new way, and researchers believe combining it with chemotherapy may offer better results than chemotherapy alone for people whose disease has progressed.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new medication (datopotamab deruxtecan) plus chemotherapy, or standard chemotherapy. The study is divided into two parts: the first part tests safety and finds the best dose with a smaller group of participants, and the second part involves a larger group comparing the new medication head-to-head against standard treatment. You will have regular clinic visits for infusions, blood tests, and scans to monitor how well the treatment is working and check for side effects. The exact length of treatment depends on how your cancer responds and how you tolerate the medication.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States